<DOC>
	<DOCNO>NCT00536601</DOCNO>
	<brief_summary>This pilot trial study different high-dose chemotherapy regimen without total-body irradiation ( TBI ) compare well work give autologous stem cell transplant ( ASCT ) treat patient hematologic cancer solid tumor . Giving high-dose chemotherapy without TBI ASCT stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood bone marrow store . More chemotherapy may give prepare stem cell transplant . The stem cell return patient replace blood form cell destroy chemotherapy .</brief_summary>
	<brief_title>High-Dose Chemotherapy With Without Total-Body Irradiation Followed Autologous Stem Cell Transplant Treating Patients With Hematologic Cancer Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate progression free survival ( PFS ) distribution Hodgkin lymphoma ( HL ) , non-Hodgkin lymphoma ( NHL ) multiple myeloma ( MM ) disease-specific high dose therapy regimen . SECONDARY OBJECTIVES : I . Estimate PFS distribution amyloidosis , acute leukemia select solid tumor disease-specific high dose therapy regimen . II . Explore role risk factor outcome treated patient . III . Examine high dose therapy regimen-related toxicity ( RRT ) overall survival bone marrow transplant ( BMT ) . OUTLINE : Patients assign condition regimen base disease , age , co-morbidities .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically confirm diagnosis malignant hematologic disorder , amyloidosis solid tumor malignancy Recurrent refractory disease disease high risk recurrence Hodgkin Disease ( HL ) : Relapsed refractory disease chemotherapy minimum one standard regimen NonHodgkin Lymphoma ( NHL ) : ( Low , Intermediate High Grade ) Relapsed refractory disease chemotherapy least one standard regimen first complete remission ( CR ) lymphoblastic small , noncleaved cell lymphoma high risk relapse high International Prognostic Index ( IPI ) Score Acute Myeloid Leukemia ( AML ) : Low High Risk disease first second CR great patient risk allogeneic transplant outweigh benefit Acute Lymphoblastic Leukemia ( ALL ) : Low high risk disease first second CR risk allogeneic transplant outweigh benefit Multiple Myeloma ( MM ) : Low high risk first great response ( stable disease well ) respond patient first progression Other Malignant Lymphoproliferative Disorders : ( chronic lymphocytic lymphoma [ CLL ] , Waldenstroms macroglobulinemia , relapse refractory disease firstline chemotherapy Amyloidosis : primary previously treat Solid Tumors : Testicular cancer patient relapse disease primary progressive disease respond salvage therapy ; relapse advancedstage newly diagnose neuroblastoma ( NBL ) small round blue cell tumor ( SRBCT ) patient 30 year age ; patient solid tumor recur follow conventional treatment high risk relapse , demonstrate chemosensitivity Patients malignancy would treat autologous stem cell transplant syngeneic donor ; syngeneic donor would consider risk autologous stem cell transplant patient Performance status 02 ( Karnofsky performance status [ KPS ] &gt; = 70 % ) ; patient amyloidosis MM decrease KPS due disease eligible Life expectancy &gt; 2 month Pulmonary function test ; diffuse capacity lung carbon monoxide ( DLCO ) diffusing volume alveolar volume ( DLVA ) &gt; = 50 % predict ; DLCO correct hemoglobin and/or alveolar ventilation Cardiac ventricular ejection fraction &gt; = 50 % radionuclide ventriculogram echocardiogram Bilirubin &lt; 3 x normal Alkaline phosphatase , serum glutamic oxaloacetic transaminase ( SGOT ) &lt; 3 x normal Calculated creatinine clearance &lt; 40 cc/min modify CockcroftGault formula adult Schwartz formula pediatrics Glomerular filtration rate renal scan neuroblastoma patient , determine dose parameter Positive cytomegalovirus ( CMV ) immunoglobulin M ( IgM ) and/or positive hepatitis serology demonstrate infection require Infectious Disease consult subsequent clearance Any active infection require Infectious Disease consult subsequent clearance Peripheral Blood Counts polymorphonuclear neutrophil ( PMN ) &gt; 1500/uL Platelet ( Plt ) &gt; 75,000/uL Prior stem cell storage : No radiation within three week stem cell harvest Bone marrow may use conjunction blood progenitor cell Hematologic Malignancy patient human immunodeficiency virus ( HIV ) positivity appropriate antiretroviral therapy may go autotransplant follow laboratory test ; ( CD4+ cell count &gt; 75 cell per microliter HIV copy number &lt; 100,000 per microliter Infectious Disease clearance Acute Leukemia , HL , NHL , MM Solid Tumor patient must receive 2 cycle chemotherapy follow diseasespecific restaging prior mobilization collection stem cell ; small round blue cell tumor patient must receive either standard therapy surgical intervention ; disease status response therapy must know prior transplant establish disease status transplant ; amyloidosis patient may proceed BMT without receive chemotherapy No serious organ dysfunction unless cause underlying disease , exclusion criterion include follow : Uncontrolled severe cardiovascular disease , include recent ( &lt; 6 month ) myocardial infarction , congestive heart failure , symptomatic angina , lifethreatening arrhythmia hypertension Active bacterial , viral , fungal infection Active peptic ulcer disease Uncontrolled diabetes mellitus No serious medical psychiatric illness Not pregnant No psychiatric condition would prevent delivery care ; psychology clearance necessary Allogeneic BMT possible , desirable Age &gt; 65 year No compatible donor identify Estimated risk graft vs. host disease complication great risk recurrence autologous BMT Adequate bone marrow blood stem cell dose obtain : For blood stem cell : total CD 34+ &gt; = 2 x 10^6/kg unable collect dose , total nucleate cell bone marrow dose &gt; = l x 10^8/kg</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>